Efruxifermin in Compensated Liver Cirrhosis Caused by MASH

202566 citationsJournal Article

Authors

Mazen Noureddin · Methodist Hospital

Mary E. Rinella · University of Chicago

Naga Chalasani · Indiana University School of Medicine

Guy Neff

K. Lucas · Lucas Research

Manuel Rodríguez

Madhavi Rudraraju · Pinnacle Clinical Research

Rashmee Patil ·

Abstract

In patients with compensated cirrhosis caused by MASH, efruxifermin did not significantly reduce fibrosis at 36 weeks. (Funded by Akero Therapeutics; SYMMETRY ClinicalTrials.gov number, NCT05039450.).

Topics & Keywords

Liver Disease Diagnosis and Treatment Hepatitis B Virus Studies Liver Diseases and Immunity

Publication Details

Published in: New England Journal of Medicine

Volume 392, Issue 24, pp. 2413-2424

DOI: 10.1056/nejmoa2502242

Field-Weighted Citation Impact: 86.88

Command Palette

Efruxifermin in Compensated Liver Cirrhosis Caused by MASH

Authors

Abstract

Topics & Keywords

Publication Details